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Background: Qian Yang Yu Yin Granule (QYYYG), a traditional Chinese herbal medicine, has been indicated for
renal damage in hypertension for decades in China, but little remains known regarding its underlying molecular
mechanism. Therefore, we performed the current study in order to investigate the underlying molecular
mechanism of QYYYG in the treatment of hypertensive renal damage.
Methods: We hypothesize that QYYYG relieves hypertensive renal injury through an angiotensin II (Ang II)-nicotinamide
adenine dinucleotide phosphate (NAPDH)-oxidase (NOX)-reactive oxygen species (ROS) pathway. In this study,
we investigated the effects of QYYYG-containing serum (QYGS) in human mesangial cells (HMCs) against Ang
II-induced cell proliferation, ROS production, and inflammation through the seropharmacological method.
Results: We found that QYGS could inhibit cell proliferation in Ang II-treated HMCs. In addition, QYGS considerably
suppressed production of ROS, decreased mRNA and protein expression of NAPDH-oxidase 4 (NOX4), p22phox, and
activated Ras-related C3 botulinum toxin substrate 1 (GTP-Rac1); as well as counteracted the up-regulation of
inflammatory markers including tumor necrosis factor-α (TNF-α), nuclear factor-κB (NF-κB) p65, and interleukin 6
(IL-6). These effects were further confirmed in HMCs transfected with specific small interfering RNA (siRNA)
targeting NOX4.
Conclusions: Taken together, these results suggest that a NOX4-dependent pathway plays an important role in
regulating the inhibitory effect of QYGS. Our findings provide new insights into the molecular mechanisms of
QYYYG and their role in the treatment of hypertensive nephropathy.
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Hypertension is one of the most common risk factors
for cardiovascular and renal diseases [1]. Recently, it has
been widely accepted that the renin-angiotensin system
(RAS) plays an essential role in the pathophysiology of
hypertension-related renal damage [2]. Numerous stud-
ies have demonstrated that angiotensin II (Ang II), the
central effector molecule of the RAS, significantly con-
tributes to the induction of irreversible renal damage
through the direct or indirect stimulation of glomerular
mesangial expansion, glomerular basement membrane
reduplication, and extracellular matrix (ECM) deposition
[3]. In addition, researchers have found that Ang II is
able to induce contraction of glomerular mesangial cells,
which contributes to the development of glomerular
atrophy and sclerosis, resulting in progressive renal
dysfunction [4,5]. Therefore, fully understanding the
underlying molecular mechanism of Ang II-induced
glomerular pathological changes has important implica-
tions for the prevention and treatment of renal damage
in hypertension.
In recent years, a considerable number of studies have
identified several specific signaling pathways that
mediate the pathogenic actions of Ang II, of which a
nicotinamide adenine dinucleotide phosphate (NADPH)-
oxidase (NOX)-dependent pathway plays a pivotal role [6]
Previous investigations have confirmed that Ang II in-
duces reactive oxygen species (ROS) generation through
the NOX system [5,7]. Then, oxidative stress from the
ROS stimulates ROS-sensitive inflammatory pathways,
such as nuclear factor-κB (NF-κB) cascade, to produce a
number of pro-inflammatory mediators and cytokines
[8,9]. These pro-inflammatory factors, together with Ang
II-induced oxidative stress, are able to cause renal vascular
remodeling and injury to the endothelia cells of renal
small arteries. These effects decrease renal blood supply,
ultimately leading to ischemic renal parenchymal injury
[10]. Hence, the blockade of Ang II has been considered a
major therapeutic strategy for hypertensive nephropathy.
Angiotensin receptor blockers (ARBs), the most widely-
used anti-hypertensive drugs, have been recommended
for use in the management of hypertensive nephropathy
by the 2013 European guidelines for the management of
arterial hypertension [11]. Numerous recent studies also
have demonstrated the protective effects of ARBs against
Ang II-induced glomerular pathological changes through
blocking oxidative stress and oxidative stress-mediated
inflammatory responses [12-14]. However, due to the
pathogenic complexity of hypertensive nephropathy,
there is still an increasing demand for novel and effect-
ive therapeutics.
In recent years, traditional Chinese medicine has shown
its advantage against hypertension and hypertension-
related complications [15]. Qian Yang Yu Yin Granule(QYYYG), a traditional Chinese herbal medicine, has been
indicated for renal damage in hypertension for decades in
China, but little remains known regarding its underlying
molecular mechanism. Polygoni Multiflori Radix, one of
the major ingredients of QYYYG, has been found to
induce potent antioxidant and anti-inflammatory effects
[16,17]. Therefore, we hypothesize that QYYYG relieves
hypertensive renal injury through an Ang II-NOX-ROS
pathway. In the present study, we investigated the effects
of QYYYG-containing serum (QYGS) in human mesan-
gial cells (HMCs) against Ang II-induced cell proliferation,
ROS production, and inflammation through the serophar-
macological method. We found that these effects of QYGS
are likely to be mediated through a NOX4-dependent
pathway, which may possibly be a molecular mechanism
behind the pharmacological effects of QYYYG.
Methods
Reagents
QYYYG (batch No.1307004) was provided by the Insti-
tute of Chinese Traditional Medicine of Jiangsu Province
(Nanjing, China). Detailed information on the compo-
nents of QYYYG and their amounts is listed in Table 1.
The preparation process of QYYYG was as follows: All
components were mixed in proportion. The mixture was
decocted with 10-fold amount of water (volume/weight)
twice, for 1 h each time. The resultant filtrates were com-
bined and concentrated to a relative density of 1.2 g/ml
(at 60°C). After adding stevioside to a concentration of 1%
(weight/volume), the concentrated filtrate was mixed with
dextrin at a weight ratio of 1:1 and granulated in a fluid-
ized bed granulator. The resulting granules were dried at
60°C for 24 h and then stored at 4°C for future use.
According to the Pharmacopoeia of the People’s Republic
of China (2010 edition) and the Quality Specifications
of Chinese Traditional Medicine of Jiangsu Province,
thin-layer chromatography (TLC) and high performance
liquid chromatogram (HPLC) methods were employed
to control the quality of QYYYG (Table 2). Valsartan
(Diovan®, batch No. X1584) was provided by Norvatis
(Basel, Switzerland).
Ang II was purchased from Sigma (St. Louis, MO,
USA). Dulbecco’s modified Eagle’s medium (DMEM),
trypsin, and fetal bovine serum (FBS) were from Life
Technologies (Carlsbad, CA, USA). Dimethyl sulfoxide
(DMSO) and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl
tetrazolium bromide (MTT) were purchased from Amresco
(Solon, OH, USA). TRNzol® Plus reagent was from
Biouniquer (Nanjing, China).
Cell culture
HMCs were provided by the Institute of Life Science
and Technology, China Pharmaceutical University
(Nanjing, China). The cells were cultured in DMEM
Table 1 The components of QYYYG
Components Chinese name Origin Amount used (g)
Polygoni Multiflori Radix He Shou Wu Polygonum multiflorum Thunb. 180
Herba Bidentis Bipinnatae Gui Zhen Cao Bidens pilosa Linnaeus 110
Corni Fructus Shan Zhu Yu Cornus officinalis 108
Scrophulariae Radix Xuan Shen Scrophularia ningpoensis 180
Alismatis Rhizoma Ze Xie Alisma orientalis 180
Cyathulae Radix Chuan Niu Xi Cyathula officinalis 170
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penicillin, and 100 mg/ml streptomycin at 37°C in a 5%
CO2 atmosphere.
Preparation of QYYYG-containing serum
Thirty Wistar rats (age of 14 weeks, weighing between
260 and 320 g) were provided by the Experimental Ani-
mal Center of Yangzhou (Yangzhou, China). The animal
experiments were conducted in accordance with the
guidelines as set forth by the National Research Council.
The study protocol was approved by the Animal Ethics
Committee of Nanjing University of Traditional Chinese
Medicine.
All animals were maintained under temperature-
controlled (22 ± 2°C) and humidity-controlled (55 ± 5%)
conditions in 12-hour light/dark cycles with free access
to sterile normal food and water. After an acclimation
period of one week, the animals were randomly divided
into three groups: the QYGS group, the valsartan-
containing serum (VS) group, and the control serum
group (n = 10 animals per group). Animals in the QYGS
group and VS group were orally administered 2.5 g/kg
of QYYYG (10-fold clinic dosage) and 13.3 mg/kg of
valsartan (10-fold of clinic dosage) once daily for 7 days.
Both drugs were suspended in 3 ml of distilled water.
One hour after the last administration of QYYYG or
valsartan on the seventh day, whole blood was obtained
from the retro-orbital venous plexus of the animals in
all groups. For all groups, serum was isolated by centrifu-
gation at 3000 rpm for 10 min after standing at room
temperature (RT) for 30 min, and then mixed with serumTable 2 Quality evaluation of QYYYG






HPLC >6 mg per 10 g
QYYYG
Polygoni Multiflori Radix TLC Contained
Herba Bidentis Bipinnatae TLC Contained
Corni Fructus TLC Contained
Cyathulae Radix TLC Contained
HPLC: high performance liquid chromatogram, TLC: thin-layer chromatography.from the same group. Then, the serum was inactivated in
a 56°C environment for 30 min and filtered with 0.22 μm
pore-size membrane. The filtered serum was aliquoted
and stored at −20°C for future use.
Cell proliferation assay
MTT assay was used to evaluate the proliferation ability
of Ang II-treated HMCs. Cells were transferred onto
96-well plates containing DMEM supplemented with 10%
FBS. The optimal cell number was found to be 1 × 104
cells/well. Cells were then treated with varying con-
centrations of Ang II (0, 10−3, 10−4, 10−5, 10−6, and
10−7 mmol/L). After 24 h, 20 μl MTT (5 mg/ml) was
added and cells were cultured for an additional 4 h.
Subsequently, the medium was removed and 150 μl
DMSO was added to each well. After 5 min of shaking at
RT, the absorbance was measured at 570 nm by a micro-
plate reader (BioTek Instruments, Winooski, VT, USA).
Assays were performed in sextuplicate and repeated four
times independently. Based on the results, 10−4 mmol/L
of Ang II was determined to be the optimal treatment
concentration for subsequent studies.
MTT assay was also used to examine the inhibitory ef-
fects of QYGS on proliferation in Ang II-treated HMCs.
The cells were cultured as described above, and then
were pre-treated with VS or QYGS in groups as follows:
the vehicle group (with medium containing 5% drug-free
rat serum), the Ang II model group (with medium con-
taining 5% drug-free rat serum), the 5% VS group (posi-
tive control, with medium containing 5% VS), the 1.25%
QYGS group (with medium containing 1.25% QYGS and
3.75% drug-free rat serum), the 2.5% QYGS group (with
medium containing 2.5% QYGS and 2.5% drug-free rat
serum), and the 5% QYGS group (with medium contain-
ing 5% QYGS). After one hour, all groups except for the
vehicle group were incubated with 10−4 mmol/L of Ang
II for 24 h. Then, MTT assay was performed to detect
cell proliferation in each group. Assays were performed
in sextuplicate and repeated four times independently.
Real time-polymerase chain reaction analysis
HMCs were cultured in 6-well plates at a density of
2 × 105 cells per well. Then, the cells were grouped and
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section. One hour later, all groups except for the
vehicle group were treated with 10−4 mmol/L of Ang II
for 1 h. Afterwards, total RNA was extracted from cells
using TRIzol Plus reagent (Biouniquer) according to
the manufacturer’s instructions. RNA concentrations
were determined by a microplate reader (BioTek In-
struments). Total cDNA was synthesized with a cDNA
synthesis kit (Biouniquer). RT-PCR was performed
using an ABI 7700 Prism Sequence Detection System
and TaqMan primer probes (Applied Biosystems, Foster
City, CA, USA). The primer sequences are presented in
Table 3. The total reaction volume was 20 μl: 5 μl cDNA,
10 μl 2 × UltraSYBR Mixture (with ROX), 0.5 μl of each
primer, and 4 μl RNase-free water. Cycle parameters were
as follows: activation at 95°C for 10 min, 40 cycles of de-
naturation at 95°C for 15 s, and then annealing and exten-
sion at 60°C for 60 s. Calculations of the expression levels
were carried out using the absolute standard curve
method [18]. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control. All experi-
ments were conducted three times independently.
Western blot analysis
HMCs were cultured, grouped, and treated as described
in the “Real time-polymerase chain reaction analysis”
section. HMCs of all groups were then harvested by
centrifugation at 1500 rpm for 5 min. The harvested
cells were washed three times with phosphate-buffered
saline (PBS, pH 7.2 – 7.4) and lysed in RIPA buffer by
shaking at 4°C for 30 min. The homogenates were centri-
fuged at 14,000 rpm for 10 min and the supernatant was
used for western blot analysis. Protein concentrations
were determined using the Bradford method according
to the manufacturer’s instructions (Beyotime Technology,
Jiangsu, China). Supernatants were mixed with sodium
dodecyl sulfate-polyacrylamidegel electrophoresis (SDS-
PAGE) sample buffer and boiled for 10 min, and were
then separated on 10% SDS–PAGE gel. Subsequently,Table 3 Primers used in RT-PCR










5′- GGAAGATGGTGATGGGATT −3′samples were transferred onto polyvinylidene difluoride
(PVDF) membranes (Bio-Rad, Hercules, CA, USA). Mem-
branes were blocked for 1 h in 5% (w/v) non-fat milk and
then incubated with a primary antibody at RT for 2 h. The
following primary antibodies were used: NOX4, p22phox,
Rac1, tumor necrosis factor-α (TNF-α), NF-κB p65, and
interleukin 6 (IL-6) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); activated Ras-related C3 botulinum toxin
substrate 1 (GTP-Rac1) (NewEast Bioscience, Malvern, PA,
USA); and β-actin (Sino Biological Inc., Beijing, China).
Following incubation, the membranes were washed
three times in TBST buffer, and then incubated with
horseradish peroxidase (HRP)-conjugated rabbit IgG
(diluted 1:5000) for 1 h at RT. After three washes with
TBST, proteins were detected using an enhanced
chemiluminescence (ECL) detection kit (Beyotime).
The immunoblotted bands were quantified by Gel-Pro
Analyzer software (version 4.0, Media Cybernetics,
Rockville, MD, USA), and the protein of interest was
normalized to β-actin. All experiments were performed
three times independently.
Reactive oxygen species generation
HMCs were cultured, grouped, and treated as described
in the “Real time-polymerase chain reaction analysis”
section. Then, 2′,7′-dichlorodihydrofluorescein diacetate
(DCHF-DA) (Beyotime) was added to each culture at a
final concentration of 10 μmol/L and incubated for
20 min at 37°C. The cells were washed with PBS three
times and cellular fluorescence was assayed using cell
flow cytometry (BD Bioscience, Bedford, MA, USA). As-
says were repeated three times independently.
Small interfering RNA against NOX4
Twenty-four hours prior to transfection, 2 × 105 HMCs
were seeded into 6-well plates and cultured in
antibiotic-free medium to obtain 50-80% confluence.
Then, transfection of 125 pmol small interfering RNA
(siRNA) against NOX4 was performed using Lipofecta-
mine 2000 (Life Technologies) according to the manufac-
turer’s instructions. The transfected HMCs were grouped
and treated the same way as described previously. A non-
specific scrambled siRNA was used as a negative control
(the RNAcon group). Cells from all groups were subjected
to RT-PCR analysis, Western blot, and ROS detection
assay.
Statistical analysis
All statistical analysis was performed using SPSS 17.0
software (SPSS Inc., Chicago, IL, USA). Data are pre-
sented as means ± standard error of the mean (SEM).
Differences between experimental groups are assessed
for statistical significance using one-way analysis of vari-
ance (ANOVA), followed by least significant difference
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son tests for equal or unequal variances, respectively.
A P value less than 0.05 was considered statistically
significant (two-tailed).
Results
Effects of Ang II on proliferation of HMGs
The effects of Ang II on proliferation of HMCs are
shown in Figure 1. We found that only 10−4 mmol/L of
Ang II could significantly promote the proliferation of
HMCs when the cells were treated with various doses of
Ang II (10−3 to 10−7 mmol/L in a 10-fold concentration
gradient) for 24 h. Therefore, 10−4 mmol/L of Ang II
was used in subsequent experiments.
Inhibitory effects of QYGS on Ang II-induced HMC
proliferation
Figure 2 presents the inhibitory effects of QYGS on Ang
II-induced HMC proliferation. As shown in Figure 2A
and B, up to 5% concentrations of either VS or QYGS
alone did not influence the proliferation of HMCs.
When HMCs were pre-incubated with various doses of
VS or QYGS (1.25%, 2.5%, and 5%) for 1 h prior to treat-
ment with 10−4 mmol/L of Ang II, cell proliferation was
significantly decreased in a dose-dependent manner,
thereby indicating that both VS and QYGS possess a po-
tent inhibitory activity against Ang II-induced HMC
proliferation (Figure 2C and D).
Inhibitory effects of QYGS on Ang II-induced ROS
production in HMCs
Figure 3 shows the inhibitory effects of QYGS on Ang II-
induced ROS production in HMCs. Using the DCFH-DA
method, we found a significant production of ROS whenFigure 1 Effects of Ang II on HMC proliferation after 24
h-treatment. Cell proliferation was assessed using the MTT
method. Data are presented as means ± SEM (n = 4). **P < 0.01
compared with the control group.HMCs were treated with 10−4 mmol/L of Ang II for 24 h
(Figure 3). However, ROS levels were considerably de-
creased after pre-incubation with 5% VS or with 1.25%,
2.5%, or 5% QYGS for 1 h prior to Ang II treatment. In
addition, a dose-dependent effect was observed for QYGS
pre-incubation. Collectively, these findings demonstrate
that QYGS is able to suppress Ang II-induced ROS gener-
ation in HMCs.
Effects of QYGS on mRNA and protein expression of NOX4,
p22phox, and Rac1/GTP-Rac1 in Ang II-treated HMCs
As previously reported, Ang II could induce activation
of NOX4 and Rac1 in mesangial cells. NOX4 forms a
heterodimer with p22phox subunits to facilitate ROS gen-
eration, while Rac1 uses Nox4-derived ROS as signal
transducers to stimulate downstream signaling cascades
[19]. In combining this information with the results
shown in Figure 3, we assumed that the inhibitory effects
of QYGS on Ang II-induced ROS production in HMCs
may be mediated by a NOX4-dependent pathway.
In the current study, we found that treatment with
10−4 mmol/L of Ang II could induce a significant in-
crease in mRNA and protein levels of NOX4, p22phox,
and activated GTP-Rac1 (Figure 4A and B). Neverthe-
less, these effects could be counteracted by 5% VS or
by QYGS in a dose-dependent manner (from 1.25% to
5%). For Rac1, however, no notable difference was
observed in its mRNA and protein expression among
all the groups. Taken together, these findings provide sup-
portive evidence that QYGS is able to suppress the activa-
tion of the NOX4-dependent pathway in Ang II-treated
HMCs, which may be responsible for attenuating Ang II-
induced ROS production.
Effects of QYGS on expression of TNF-α, NF-κB p65, and
IL-6 in Ang II-treated HMCs
In taking into consideration that ROS-induced oxidative
stress plays an essential role in activating inflammatory
pathways in pro-inflammatory responses [20], we inves-
tigated the effects of QYGS on the expression of inflam-
matory markers, including TNF-α, NF-κB p65, and IL-6.
As shown in Figure 5, treatment with 10−4 mmol/L of
Ang II induced a significant increase in the protein
expression of these inflammatory markers. After incuba-
tion with 5% VS or with 1.25%, 2.5%, or 5% QYGS for
1 h prior to Ang II treatment, the effects of Ang II on
the expression of the three marker proteins were signifi-
cantly counteracted. These results indicate that QYGS is
able to prevent Ang II-induced pro-inflammatory re-
sponses in HMCs.
Silencing RNA against NOX4 in Ang II-treated HMCs
For further analysis, we employed siRNA to silence NOX4
expression in HMCs. After transfection with NOX4
Figure 2 Effects of QYGS on Ang II-induced HMC proliferation assessed by MTT assay. (A) Effect of VS (0, 1.25%, 2.5%, 5%, 10%, and 20%)
on cell proliferation after 24 h-incubation. (B) Effect of QYGS (0, 1.25%, 2.5%, 5%, 10%, and 20%) on HMC proliferation following incubation for
24 h. (C) and (D) Inhibitory effects of varying doses of VS or QYGS (1.25%, 2.5%, and 5%) on cell proliferation in Ang II-treated HMCs. Data are
presented as means ± SEM (n = 4). **P < 0.01 as compared with the control group or the vehicle group. #P < 0.05, ##P < 0.01 as compared with the
Ang II model group.
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sion of NOX4, p22phox, and GTP-Rac1 in HMCs had
decreased by 72.7%, 69.3%, and 61.8%, respectively, which
was statistically significant as compared with the RNAcon
group (Figure 6A). These results demonstrate that theFigure 3 Effects of QYGS on Ang II-induced ROS production
in HMCs assessed by DCFH-DA assay. Data are expressed as
means ± SEM (n = 3). **P < 0.01 as compared with the vehicle
group. ##P < 0.01 as compared with the Ang II model group.transfection of NOX4 siRNA was successful with a silen-
cing efficiency of over 70%. After cells transfected with
NOX4 siRNA were treated with 10−4 mmol/L of Ang II
for 24 h, we found that mRNA expression levels of p22phox
and GTP-Rac1 were still significantly increased as com-
pared with the vehicle group, indicating that the NADPH-
oxidase activity was not completely inhibited upon siRNA
knockdown of NOX4 and that other NADPH-oxidases
may be activated by Ang II, thereby leading to up-
regulation of p22phox and GTP-Rac1 expression. When
cells were pre-incubated with 5% VS or with 1.25%, 2.5%,
or 5% QYGS for 1 h followed by Ang II stimulation, the
expression levels of p22phox and GTP-Rac1 were signifi-
cantly decreased; and a dose-dependent effect was noted
for QYGS pre-incubation. For Rac1, however, no signifi-
cant difference was observed in mRNA levels among the
groups overall. Similar results showing decreased protein
levels of p22phox and GTP-Rac1 in QYGS-pretreated
HMCs were also obtained by Western blot analysis
(Figure 6B).
Furthermore, we examined ROS production in siRNA-
transfected HMCs, the results of which are shown in
Figure 7. After transfection with NOX4 siRNA for 24 h,
DCFH-DA assay showed that the ROS production in
Figure 4 QYGS counteracts Ang II-induced up-regulation of NOX4, p22phox, and GTP-Rac1 in HMCs. Cells were pre-incubated with 5% VS
or with 1.25%, 2.5%, or 5% QYGS for 1 h prior to treatment with 10−4 mmol/L of Ang II. RT-PCR and Western blot were carried out to detect
mRNA (A) and protein levels (B). Data are expressed as means ± SEM (n = 3). **P < 0.01 as ompared with the vehicle group. #P < 0.05, ##P < 0.01 as
compared with the Ang II model group.
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RNAcon group. However, treatment with 10−4 mmol/L of
Ang II was able to induce a considerable increase in ROS
production in siRNA-transfected cells. When cells were
pre-treated with 5% VS or various doses of QYGS, thisFigure 5 Effects of QYGS on protein expression of TNF-α, NF-κB P65, an
presented as means ± SEM (n = 3). **P < 0.01 as compared with the vehicle ginductive effect of Ang II could be significantly inhibited,
further demonstrating the ability of QYGS to inhibit Ang
II-induced ROS generation in HMCs.
In order to further verify the effects of QYGS on sup-
pressing Ang II-induced pro-inflammatory responses, wed IL-6 in Ang II-treated HMCs as assessed by Western blot. Data are
roup. #P < 0.05, ##P < 0.01 as compared with the Ang II model group.
Figure 6 QYGS suppresses Ang II-induced up-regulation of NOX4, p22phox, and GTP-Rac1 in NOX4 siRNA-transfected HMCs. RT-PCR
(A) and Western blot analysis (B) results of the effects of QYGS on NOX4, p22phox, and GTP-Rac1 upon transfection with non-targeting siRNA or
NOX4 siRNA. Data are presented as means ± SEM (n = 3). **P < 0.01 as compared with the RNAcon group. #P < 0.05, ##P < 0.01 as compared with
the vehicle group. $P < 0.05, $$P < 0.01 as compared with the Ang II model group.
Figure 7 Effects of QYGS on Ang II-induced ROS production in
NOX4 siRNA-transfected HMCs as assessed by DCFH-DA assay.
Data are expressed as means ± SEM (n = 3). **P < 0.01 as compared
with the RNAcon group. ##P < 0.01 as compared with the vehicle
group. $$P < 0.01 as compared with the Ang II model group.
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IL-6 in HMCs after siRNA transfection. As shown in
Figure 8, siRNA knockdown of NOX4 led to a consider-
able decrease in expression of the three inflammatory
marker proteins as compared to the RNAcon group.
When cells were incubated with Ang II, incubation
caused a notable increase in the protein levels of all
inflammatory markers. However, this effect was counter-
acted by pre-treatment with 5% VS or various doses of
QYGS.
Discussion
In the current study, we report for the first time that
QYGS has inhibitory effects on Ang II-induced prolifera-
tion in HMCs. Furthermore, we found that QYGS is able
to attenuate Ang II-induced ROS generation and pro-
inflammatory responses in cells. These effects may be
mediated by an NOX4-dependent pathway.
Figure 8 Effects of QYGS on Ang II-mediated up-regulation TNF-α, NF-κB P65, and IL-6 in NOX4 siRNA-transfected HMCs as assessed
by Western blot analysis. Data are presented as means ± SEM (n = 3). **P < 0.01 as compared with the RNAcon group. #P < 0.05, ##P < 0.01 as
compared with the vehicle group. $$P < 0.01 as compared with the Ang II model group.
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erular mesangium, and renal fibrosis have been consid-
ered to be the main pathogenic factors behind renal
damage in hypertension [21]. Hyperplasia of the glom-
erular mesangium is characterized by the proliferation of
glomerular mesangial cells and excessive ECM accumu-
lation [21,22]; while the key feature of renal fibrosis is
the accumulation of myofibroblasts and ECM deposition
[23]. Therefore, both the proliferation of glomerular
mesangial cells and ECM deposition have been impli-
cated as two key events in the progression of renal dam-
age [24]. RAS, and particularly Ang II, is well known to
be involved in a wide variety of cardiovascular patholo-
gies including hypertension [2]. Researchers have dem-
onstrated that Ang II is able to stimulate glomerular
mesangial cell proliferation and ECM deposition, conse-
quently causing glomerular sclerosis and additional renal
damage [3]. It is therefore widely accepted that inhib-
ition of Ang II-induced glomerular mesangial cell prolif-
eration and ECM deposition should be an effective
approach to preventing the development or progression
of renal damage in hypertension [25,26]. In the current
study, we found that pre-treatment with various doses of
QYGS (from 1.25% to 5%), like pretreatment with 5%
VS, could effectively inhibit Ang II-induced HMC prolif-
eration. This effect may be due to the antioxidant and
anti-inflammatory properties of the active components
of QYYYG.
QYYYG contains six Chinese medical herbs, of which
Polygoni Multiflori Radix is the major active component
and has been indicated for the treatment of hypertension
and hypertension-related renal diseases in Chinese Trad-
itional Medicine for a number of decades. In recent
years, numerous studies have proven that 2,3,5,4′-tetra-
hydroxystilbene-2-O-β-D-glucopyranoside (THSG) is
the main active substance in Polygoni Multiflori Radix,
which produces potent activity against the oxidative
stress that follows acute inflammation [27-29]. In ourstudy, although QYGS was used instead of QYYYG as
intervention in HMCs, HPLC analysis showed that there
was a high content of THSG in QYGS (data not shown).
Furthermore, researchers have reported that some active
substances extracted from Corni Fructus, such as 7-O-
galloyl-D-sedoheptulose and loganin, have potent pro-
tective effects against diabetes- or glycerol-induced renal
injury through elimination of ROS and inhibition of
inflammation [30,31]. Therefore, we assume that the
antioxidant and anti-inflammatory activity of these com-
pounds may be involved in the inhibitory effect of QYGS
on Ang II-induced HMC proliferation.
Recently, many studies have confirmed that oxidative
stress and inflammation are important hallmarks of renal
damage in hypertension [32,33]. As the key component of
RAS, Ang II induces oxidative stress and inflammation by
activating the Ang II type 1 (AT1) receptor [34]. Under
pathological conditions, inflammatory changes induced by
Ang II can lead to proliferation of mesangial cells and loss
of the mesangial matrix, followed by excessive production
of ECM and mesangial expansion [2]. Growing evidence
suggests that these effects of Ang II are mainly mediated
via activation of NOXs [7]. Researchers have demon-
strated that NOXs are widely expressed in renal tissue
[35]. Currently, at least four NOXs (NOX1, NOX2,
NOX4, and NOX5) have been identified, of which NOX4
shows the highest expression level [36]. Recent studies
have indicated that NOX4 is associated with p22phox and
serves as an important source of ROS; while Rac1 uses
Nox4-derived ROS to elicit downstream signaling path-
ways [36,37]. Gorin et al. have provided definitive evidence
that Ang II is able to induce activation of NOX4 and Rac1
in mesangial cells [19]. In line with their findings, we also
found that incubation with 10−4 mmol/L of Ang II could
not only induce a significant increase in ROS production
in HMCs, but could also considerably enhance the mRNA
and protein levels of NOX4, p22phox, and activated
GTP-Rac1 as compared to the vehicle group. When
Ding et al. BMC Complementary and Alternative Medicine  (2015) 15:81 Page 10 of 11cells were pre-treated with QYGS, we found that QYGS
was able to decrease ROS production and down-
regulate mRNA and protein expression of NOX4,
p22phox, and GTP-Rac1 in Ang II-treated HMCs. These
results suggest that these effects of QYGS may be medi-
ated through a NOX4-dependent pathway. Neverthe-
less, when NOX4 was silenced by siRNA in HMCs, Ang
II was able to facilitate ROS production and expression
of the aforementioned molecules to at least some extent;
but these effects were still counteracted by intervention
with QYGS. According to previous literature, Ang II is
also functionally associated with NOX1, NOX2, and
NOX5 [36]. Therefore, these findings imply that other
NOXs might also be involved in the antioxidant potency
of QYGS. However, extensive studies are required to con-
firm this.
Numerous studies have revealed that ROS production
upon Ang II-induced NOX activation promotes down-
stream inflammatory responses, which are critical for
the development and progression of renal damage in
hypertension [38,39]. The signaling pathways involved in
this process include NF-κB, STAT, and MAPK pathways,
which can be activated by ROS to regulate the gene ex-
pression of numerous cytokines, as well as adhesion and
chemoattractant molecules [40]. In this study, we found
that QYGS is able to inhibit the Ang II-induced protein
expression of TNF-α, NF-κB p65, and IL-6 in HMCs.
This finding demonstrates the inhibitory effect of QYGS
on Ang II-induced pro-inflammatory responses, which is
assumed to be related to the negative impact of QYGS
on Ang II/NOX pathway. However, a thorough under-
standing of how the active ingredients in QYGS, such as
THSG, exert their signaling functions still awaits further
research.
One possible limitation to this study should be
noted. According to Cao et al., rat and human exhibit
different expression levels and patterns for metaboliz-
ing enzymes in the intestine [41]. Hence, it is reason-
able to assume that the metabolism of QYYYG in rat
may be different with that in human, and that the use
of QYGS might introduce a bias into the results of this
study. Therefore, further studies using QYYYG-
containing human serum are required to validate the
present findings.
Conclusions
In summary, the current study shows that QYGS is able
to inhibit cell proliferation, ROS production, and in-
flammation in Ang-II-treated HMCs. Our data suggest
that an NOX4-dependent pathway plays an important
role in regulating the inhibitory effect of QYGS. These
findings provide new insights into the molecular mecha-
nisms of QYYYG in the treatment of renal damage in
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